Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986179 alone and with nivolumab in advanced solid tumors
NL-OMON47607Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986179 and nivolumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 4 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability. Started Sep 2016; status: completed.
02
Drugs
BMS-986179nivolumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)prostate cancer (PCa)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON47607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47607.